EP
CRL icon

Edgestream Partners’s Charles River Laboratories CRL Stock Holding History

Edgestream Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Buy
10,841
+1,805
+20% +$321K 0.07% 454
2026
Q1 		$1.56M Buy
+9,036
New +$1.68M 0.05% 551
2025
Q4 		– Sell
-26,667
Closed -$4.17M – 973
2025
Q3 		$4.17M Buy
26,667
+14,820
+125% +$2.35M 0.12% 312
2025
Q2 		$1.8M Buy
+11,847
New +$1.58M 0.05% 548
2025
Q1 		– Sell
-12,880
Closed -$2.38M – 880
2024
Q4 		$2.38M Buy
+12,880
New +$2.48M 0.1% 360
2024
Q3 		– Sell
-16,725
Closed -$3.46M – 877
2024
Q2 		$3.46M Buy
+16,725
New +$3.79M 0.17% 207
2022
Q1 		– Sell
-9,672
Closed -$3.64M – 549
2021
Q4 		$3.64M Buy
9,672
+5,524
+133% +$2.15M 0.23% 140
2021
Q3 		$1.71M Buy
+4,148
New +$1.72M 0.11% 258

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Edgestream Partners's CRL Position: Q2 2026 in Review

Edgestream Partners increased its Charles River Laboratories (CRL) stake by 20% in Q2 2026, buying an estimated $321K and bringing the position to 10,841 shares worth $2.46M. The position accounts for 0.07% of the portfolio, ranked #454.

Edgestream Partners first reported a position in CRL in Q3 2021 and has held it in 8 quarters since. The position peaked at $4.17M in Q3 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Edgestream Partners held 10,841 shares of Charles River Laboratories worth $2.46M as of Q2 2026.
  • Edgestream Partners bought 1,805 Charles River Laboratories shares in Q2 2026, an estimated $321K.
  • Charles River Laboratories made up 0.07% of Edgestream Partners's portfolio in Q2 2026, its #454 holding.
  • Edgestream Partners first reported a position in Charles River Laboratories in Q3 2021 and has held it in 8 quarters since.
  • Edgestream Partners's Charles River Laboratories position peaked at $4.17M in Q3 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.